Fundz

Edesa Biotech, Inc. reported raising in an initial SEC Form D filing

PUBLIC · EDSAApr 05, 2022

Round Type

Venture

MarkhamBiotechnologyTherapeuticsPharmaceuticalBiopharma

Quick answer

Edesa Biotech raised an undisclosed amount in a funding round, dated April 5, 2022. Edesa Biotech is based in Markham, Ontario, Canada.

How much did Edesa Biotech raise?
Edesa Biotech raised an undisclosed amount in a funding round on April 5, 2022.
What does Edesa Biotech do?
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases.
Where is Edesa Biotech based and how big is it?
Edesa Biotech is based in Markham, Ontario, Canada. Fundz records about 20 employees.
Who are the decision-makers at Edesa Biotech?
Fundz holds 3 contacts at Edesa Biotech, including the Director of Business Development. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Edesa Biotech that raised within 45 days of this round, from Fundz verified event records.

  • Cumulus Oncology raised $5.4M on February 22, 2022.
  • Tempest Therapeutics raised $15M on May 11, 2022.
  • Zentalis Pharmaceuticals raised $25M on April 27, 2022.
  • BioXcel Therapeutics raised $260M on April 19, 2022.
  • BioNTech raised $150M on April 14, 2022.
  • Theriva Biologics raised $1.5M (Seed) on March 21, 2022.

Who to call at Edesa Biotech, and when

A new round usually means Edesa Biotech is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Edesa Biotech raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Edesa Biotech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Edesa Biotech. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Edesa Biotech

Location

100 SPY COURT

Markham, Ontario, Canada

About

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Edesa Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsLeo B., Director of Business Development hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Edesa Biotech's next move

See what Strategic adds

Edesa Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.